Elisabetta Coppola

Naples, 80131, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Real-World Analysis of Metastatic Renal Cell Carcinoma Patients Treated with Pembrolizumab Plus Axitinib: Evidence from the Campania Oncology Network.

Real-World Analysis of Metastatic Renal Cell Carcinoma Patients Treated with Pembrolizumab Plus Axitinib: Evidence from the Campania Oncology Network.

Journal: Current oncology (Toronto, Ont.)

Published: April 22, 2026

Establishment of the Campania Oncology Network (Rete Oncologica Campana, ROC): a paradigm shift in oncological care and real world research in the Campania region.

Establishment of the Campania Oncology Network (Rete Oncologica Campana, ROC): a paradigm shift in oncological care and real world research in the Campania region.

Journal: ESMO real world data and digital oncology

Published: February 06, 2026

Physical Activity, Nutritional Status, and Health-Related Quality of Life in Newly Diagnosed Cancer Patients: Evidence from the NUTRISCREEN Project.

Physical Activity, Nutritional Status, and Health-Related Quality of Life in Newly Diagnosed Cancer Patients: Evidence from the NUTRISCREEN Project.

Journal: Nutrients

Published: February 02, 2026

Cancer in migrant populations: evidence from a regional oncology network.

Cancer in migrant populations: evidence from a regional oncology network.

Journal: BMC public health

Published: January 23, 2026

Real-world outcomes of second-line pembrolizumab in urothelial carcinoma: a multicenter analysis from the Campania Oncological Network (ROC).

Real-world outcomes of second-line pembrolizumab in urothelial carcinoma: a multicenter analysis from the Campania Oncological Network (ROC).

Journal: BMC cancer

Published: January 20, 2026

PARPi and myeloid neoplasms; the Italian MITO-MaNGO experience based on a multicentric survey.

PARPi and myeloid neoplasms; the Italian MITO-MaNGO experience based on a multicentric survey.

Journal: ESMO open

Published: August 20, 2025

The impact of body mass index on survival and surgical outcomes in ovarian cancer: insights from the MITO trials.

The impact of body mass index on survival and surgical outcomes in ovarian cancer: insights from the MITO trials.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: July 29, 2025

Optimizing Nutritional Care with Machine Learning: Identifying Sarcopenia Risk Through Body Composition Parameters in Cancer Patients-Insights from the NUTritional and Sarcopenia RIsk SCREENing Project (NUTRISCREEN).

Optimizing Nutritional Care with Machine Learning: Identifying Sarcopenia Risk Through Body Composition Parameters in Cancer Patients-Insights from the NUTritional and Sarcopenia RIsk SCREENing Project (NUTRISCREEN).

Journal: Nutrients

Published: March 21, 2025

Association of peripheral monocytic myeloid-derived suppressor cells with molecular subtypes in single-center endometrial cancer patients receiving carboplatin + paclitaxel/avelumab (MITO-END3 trial).

Association of peripheral monocytic myeloid-derived suppressor cells with molecular subtypes in single-center endometrial cancer patients receiving carboplatin + paclitaxel/avelumab (MITO-END3 trial).

Journal: Cancer immunology, immunotherapy : CII

Published: January 16, 2025

The CXCR4 antagonist R54 targets epithelial-mesenchymal transition (EMT) in human ovarian cancer cells.

The CXCR4 antagonist R54 targets epithelial-mesenchymal transition (EMT) in human ovarian cancer cells.

Journal: PloS one

Published: August 02, 2024

KIR2DL2/DL3+NKs and Helios+Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer.

KIR2DL2/DL3+NKs and Helios+Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: March 08, 2024

Complete and early response to cemiplimab associated to severe immune toxicity in advanced cervical cancer: a case report.

Complete and early response to cemiplimab associated to severe immune toxicity in advanced cervical cancer: a case report.

Journal: Frontiers in immunology

Published: September 28, 2023

Showing 1-12 of 17

Last Updated: 09/26/2026